Cancer cell line selection serves as a milestone step for anti-cancer drug discovery. In this brief communication an attempt has been made to reviewed distinct human cancer (liver cancer, lung cancer, breast cancer, lymphoma, colon cancer, melanoma, leukemia, myeloma tumors, gastric cancer, promyelocytic leukemia, pancreatic adenocarcinoma, skin fibroblast cells, colorectal adenocarcinoma, oral squamous cell carcinoma, gynaecological cancer, larynx cancer, epithelial carcinoma etc.) cell lines (BEL-7402, NSCLC, NCI-H125, H157, MCF-7, MDA-MB- 435, KATOIII, HL-60, Mia PaCa-2, NF-103, MCF-7, SK-OV-3, CAOV-3, RL95–2, KLE etc.) which have been screened by Cell proliferation/cytotoxicity assay, MTT assay, Radioimmunoassay, TUNEL assay, Anchorage independent clonogenic assay, Neyfakh assay, Caspase-3/9 assay etc. After the in vitro screen, the most sensitive cancer cell lines can be selected for further tested in xenograft or orthotopic tumor models in mice or rats (in vivo).